Project Grant R01CA303638
Award Date 9/9/25
Completion Date 8/31/30
Dollars Obligated $370K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award in the amount of $449,625.00 was issued on September 15, 2025 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The award supports the development of statistical methods to quantify heterogeneous cell-cell interaction patterns in spatial transcriptomics data across various human diseases, including pancreatic cancer, gastric cancer, and Alzheimer's disease. The key products...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- The University of Texas MD Anderson Cancer Center was awarded a $597,289 Cooperative Agreement from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) on July 9, 2025. The objective of this project is to develop a chimeric RNA-driven neopeptide vaccine for the prevention of breast cancer in individuals with germline BRCA1/2 mutations. The research aims to identify and validate MHC Class I immunogenic peptides generated from chimeric mRNA transcripts that can serve...
- This federal Project Grant award of $194,914 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the role of trans-acting factors and cis-element sequences in activating oncogenes in rearranged human genomes. The awardee, the University of Texas Health Science Center at Houston, will employ CRISPR/Cas9 genome engineering to introduce chromosomal translocations near oncogenes and model their expression using single-cell multi-omic...
- The University of Texas MD Anderson Cancer Center received a $2,457,127 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support the "INHANCE: Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery" research project. The goal of this 5-year project, starting August 18, 2025, is to leverage advanced imaging and computational analysis to better predict, detect, prevent, and manage normal tissue injury in head and...
- This Project Grant award of $420,400 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by the University of Texas MD Anderson Cancer Center to explore cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors in MTAP-loss tumor cells. The research aims to address the challenge of innate and acquired resistance observed in 40-60% and 20-30% of MTAP-loss cancer patients, respectively, when treated with these novel...
- The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 11, 2025. The grant supports the development of a novel "Microbial-Inspired Immune-Stimulating Antibody-Toxin Conjugate (ATC) for Cancer Immunotherapy". The project aims to engineer an ATC that combines an anti-CD47 antibody with the Listeria monocytogenes toxin LLO, linked via a cleavable linker. This ATC is...
- The National Cancer Institute (NCI) awarded a 5-year, $676,584 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center (MD Anderson). The grant aims to investigate the genomic evolution and tumor microenvironment dynamics that drive metastatic progression in triple-negative breast cancer (TNBC). Specifically, the project will leverage a postmortem tissue collection program and advanced single-cell genomics techniques to...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...